Novo says new Ozempic shows lower cardiovascular risk compared with Lilly’s MounjaroOn Tuesday, Novo Nordisk said that a real-world study found that adults with type 2 diabetes who took an increased dose of its diabetes drug, Ozempic, had fewer major cardiovascular events compared to those. ..
GrowthPakistan brings you the latest news to keep an eye on Pakistan’s startup ecosystem. Business keeps you growing when you stay aware of your competitors' moves. GrowthPakistan offers Business, Tech, Global Tech, Global, Auto, and Startup News straight from industries all around the globe. This platform will help you identify upcoming opportunities not only in Pakistan but worldwide.
Email : growthpakistan@gmail.com
Whatsapp : +92320-9497079
© growthpakistan